Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
- Conditions
- Diabetes MellitusDiabetes Mellitus, Type 2Endocrine System DiseasesMetabolic DiseaseType 2 Diabetes Mellitus (T2DM)Glucose Metabolism DisordersHypoglycemic Agents
- Interventions
- Drug: Oral antihyperglycemics
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 591
- Registration Number
- NCT04809220
- Locations
- 🇯🇵
Ota Diabetes Internal Medicine Clinic, Nagano, Japan
🇯🇵Heiwadai Hospital, Miyazaki, Japan
🇯🇵Hachioji Diabetes Clinic, Hachioji, Tokyo, Japan
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
- Conditions
- Cystic FibrosisDiabetesPancreatic InsufficiencyAbnormal Glucose Tolerance
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT04731272
- Locations
- 🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 26
- Registration Number
- NCT04687514
- Locations
- 🇨🇭
University Hospital Basel, Endocrinology, Diabetes and Metabolism, Basel, Switzerland
A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes
- Conditions
- Type 2 DiabetesHealthy
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 67
- Registration Number
- NCT04641312
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇩🇪Profil Mainz, Mainz, Germany
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 291
- Registration Number
- NCT04591626
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou Shi, Henan, China
🇨🇳The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of LY3493269 in Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT04515576
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04466904
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, China
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
- Conditions
- Glucose IntoleranceOverweight and ObesityDrug EffectAdiposity
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 23
- Registration Number
- NCT04387201
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04374578
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, China
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13299
- Registration Number
- NCT04255433
- Locations
- 🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸VA Pacific Islands Health Care System, Honolulu, Hawaii, United States
🇺🇸Elite Clinical Trials, Blackfoot, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.